Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on LinkedIn about recent paper he and his colleagues co-authored:

“Delighted to share our latest publication in American Society of Clinical Oncology (ASCO) Journal JCO Precision Oncology – courtesy of our brilliant colleagues from London led by Dr. Elisa Fontana.

FGFR is clearly a tissue-agnostic target but we need to find the right dose for the right patient with right alteration.

Thrilled to collaborate with amazing colleagues Tobias Arkenau, Charles Swanton.”

Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials

Authors: Rafael Grochot, Tobias Arkenau, Charles Swanton, Vivek Subbiah, Elisa Fontana, et al.

Vivek Subbiah: Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies